Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 26;37(10):2006–2016. doi: 10.1038/s41375-023-02010-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Three adult, female cynomolgus monkeys were randomized into treatment groups and received 0.3, 1, or 3 mg/kg 1B7/CD3 via iv bolus on Day 1 and Day 8. Monkeys were observed at least twice daily for moribundity and mortality and were monitored closely for the first four hours following each dose administration. A 1B7/CD3 plasma exposure at indicated time points in cynomolgus monkeys treated with 0.3, 1, or 3 mg/kg 1B7/CD3. Data are shown as mean ± SD. B–D Concentrations of (B) white blood cells (WBC), (C) lymphocyte, and (D) monocyte at indicated time points in cynomolgus monkeys treated with 0.3, 1, or 3 mg/kg 1B7/CD3. Cell counts were performed by a hematological analyzer. E Dynamic change in CD3 positive T cells in the blood collected at indicated time points in cynomolgus monkeys treated with 0.3, 1, or 3 mg/kg 1B7/CD3. F, G Dynamic changes of (F) CD69 and (G) CD25 expression in T cells in the blood collected at indicated time points in cynomolgus monkeys treated with 0.3, 1, or 3 mg/kg 1B7/CD3. H Induction of cytokine levels by 0.3, 1, or 3 mg/kg 1B7/CD3 treatment in cynomolgus monkeys at indicated time points.